ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Estrogen Alone Didn’t Increase Lung Cancer Mortality In WHI

August 27, 2010

Henderson Committee Final Recommendation Made On P01s

February 10, 1984

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

Lung Cancer Clinical Trials Cost-Effective Alternative

October 31, 2003

Misconduct Finding Is ‘Rare,’ OSI official Tells NCAB

June 14, 1991

Academic Oncologists Reluctant To Give ESAs In Adjuvant Breast Cancer Setting.

December 7, 2007